Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 03-17-2021, 12:06 PM #1
ashleyk ashleyk is offline
Member
 
Join Date: Oct 2006
Location: New England
Posts: 253
10 yr Member
ashleyk ashleyk is offline
Member
 
Join Date: Oct 2006
Location: New England
Posts: 253
10 yr Member
Default Ytx-7739

Something to watch?


Press Releases - Yumanity Therapeutics


BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study of its lead program, YTX-7739, that demonstrate pharmacological, physiological and behavioral pre-clinical proof of concept in a Parkinsonís disease (PD) mouse model. This oral presentation and two posters will be presented at the 15th Annual International Conference on Alzheimerís and Parkinsonís Diseases (AD/PDô 2021) Virtual Conference, March 9 to 14, 2021.
ďEvidence suggests that α-synuclein pathology is a strong risk factor for Parkinsonís disease,Ē said Dan Tardiff, Ph.D., interim Head of Research and Scientific Co-founder at Yumanity Therapeutics. ďOur proprietary discovery platform led us to the target stearoyl-CoA desaturase (SCD), which when inhibited decreases the toxicity associated with pathogenic α-synuclein. Inhibition of SCD, an enzyme involved in lipid metabolism, has been shown to prevent α-synuclein pathology in multiple models, including patient-derived neurons, in vitro. The results from the current study demonstrate that YTX-7739 has a similar effect in a mouse model of Parkinsonís disease-related pathology. These results lend additional evidence to support our ongoing clinical program in Parkinsonís disease patients.Ē
The research entitled, YTX-7739, A Clinical Stage Stearoyl-CoA Desaturase Inhibitor for Parkinsonís Disease Improves Behavioral and Pathological Features in an a-Synuclein Mouse Model, conducted in collaboration with the laboratories of Silke Nuber, Ph.D., and Dennis Selkoe, M.D., at Brigham & Womenís Hospital, will be presented at 12:30 p.m. [CET] on March 13 (live discussion March 13 from 5:30 to 6 p.m. CET) by Dr. Tardiff. The study evaluated YTX-7739 vs. control in the PD mouse model. The model was used to evaluate the effect of the drug on motor function as well as survival of neurons and associated biochemical features. The effects of the drug on lipid metabolism were also examined. The investigators found:
  1. YTX-7739 prevented motor function deficits in the diseased mice after four months of YTX-7739 oral dosing compared to placebo-treated mice.
  2. YTX-7739 concentrations in the brain reached a level that engaged and inhibited SCD activity consistent with in vitro studies. In addition, SCD inhibition by YTX-7739, which can be measured by a quantitative biomarker, resulted in a decrease in monounsaturated fatty acids in both plasma and brain. Monounsaturated fatty acids may contribute to α-synuclein pathology.
  3. Multiple biochemical measures of α-synuclein pathology were significantly improved in mice with YTX-7739 as compared to controls, including levels of pathological α-synuclein. The reduction in levels of pathological α-synuclein was also confirmed via histopathological analysis.
  4. Mice treated with YTX-7739 exhibited enhanced survival of dopaminergic neurons, the type of neuron that selectively dies in the brains of patients with Parkinsonís disease.
The results indicate that YTX-7739 actively engages with its intended target, SCD, in the mouse brain. The observed improvements in pathology and neuron survival, and the resultant correction of motor dysfunction in mice provided added evidence for SCD inhibition as a potential treatment approach for Parkinsonís disease, and further support for the on-going evaluation of YTX-7739 in humans.
ashleyk is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Atticus (03-17-2021)

advertisement
Old 03-25-2021, 09:13 AM #2
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,859
10 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,859
10 yr Member
Default Thanks

Thanks for this!
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here ó it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Reply

Tags
ÓĪ-synuclein, parkinson‚Äôs, pathology, scd, ytx-7739

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -5. The time now is 09:18 AM.

Powered by vBulletin • Copyright ©2000 - 2021, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2021 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.